The International Diabetes Federation estimates that more than 285
million people world-wide have diabetes and 438 million people will
have this disease within 20 years. Type 2 Diabetes Mellitus (T2DM)
accounts for more than 90% of all diabetes and is characterized by
insulin resistance combined with relatively reduced insulin
secretion. The seven major markets for diabetes are expected to grow
to 35 billion in 10 years driven by patient population expansion and
Come and join other diabetes experts at GTC’s 6th Diabetes Drug
Discovery and Development Conference and hear key thought-leader`s
opinions to these questions and many more. This important meeting
will be held on April 29-30, 2013 in Boston, MA. The conference will
bring together the leading experts on diabetes from both industry
and academia to discuss novel targets for diabetes, lessons to learn
from current and clinical drug development.
Sessions for the 6th Diabetes Drug Discovery and Development are
currently being developed, below are sessions from the 2012
Regulatory Guidance and Updates (joint session)
New Therapeutic Targets for Diabetes
Clinical Drug Development in Diabetes
Diabetes and the Metabolic Syndrome Drug Development
Beta Cell Regenerative Therapy for Diabetes
Panel Discussion: Diabetic Devices & Technology
Panel Discussion: Beyond HbA1c - Are there Better Endpoints for
To view the agenda, click here.
To view the speaker list, click here.
The conference will run parallel with the other exciting conferences
- 3rd Diabetes Partnering and Deal-making track
Sign up for the summit pass to have access to both tracks of the
summit. Or bring a team of 3 for the price of 2 by registering with
the coupon code rcdvb!
2012 Conference Advisory Committee
ALL 2012 GTCbio Conferences
for only $3995
industry rate or $1990 acad/govt rate.
here to sign up!